DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Paroxysmal Nocturnal Hemoglobinuria - Pipeline Review, H1 2017" report to their offering.
Pharmaceutical and Healthcare latest pipeline guide Paroxysmal Nocturnal Hemoglobinuria - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Paroxysmal Nocturnal Hemoglobinuria (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Paroxysmal Nocturnal Hemoglobinuria (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Paroxysmal Nocturnal Hemoglobinuria and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 6, 2, 13 and 1 respectively.
Paroxysmal Nocturnal Hemoglobinuria (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:
- Report Coverage
- Paroxysmal Nocturnal Hemoglobinuria - Overview
- Paroxysmal Nocturnal Hemoglobinuria - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Paroxysmal Nocturnal Hemoglobinuria - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Paroxysmal Nocturnal Hemoglobinuria - Companies Involved in Therapeutics Development
- Achillion Pharmaceuticals Inc
- Akari Therapeutics Plc
- Alexion Pharmaceuticals Inc
- Alnylam Pharmaceuticals Inc
- Amgen Inc
- Apellis Pharmaceuticals Inc
- F. Hoffmann-La Roche Ltd
- ISU ABXIS Co Ltd
- Novartis AG
- NovelMed Therapeutics Inc
- Omeros Corp
- Ra Pharmaceuticals Inc
- Regeneron Pharmaceuticals Inc
For more information about this report visit http://www.researchandmarkets.com/research/zn5bm5/paroxysmal